Chronic News and Research

RSS

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

OptiNose Inc. announced today that a subgroup analysis of positive Phase II trial results has been published in the July/August issue of the American Journal of Rhinology & Allergy.

11 Aug 2010

ACR announces revised classification criteria for rheumatoid arthritis

The American College of Rheumatology announced the release of revised classification criteria (created in collaboration with the European League Against Rheumatism) for rheumatoid arthritis, which will allow the study of treatments for RA at much earlier stages of the disease—before joint damage occurs—ultimately leading to better patient outcomes.

11 Aug 2010

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.

11 Aug 2010

Dems continue push to sell health reform's benefits, GOP pushes back

The administration has struggled to sell senior citizens on the new health law, Politico reports. Here's why: "They know little about the early benefits the law has offered but remember last year's heated town halls, replete with death panels and rationing. And anti-health-reform rhetoric is generally proving to have considerable staying power."

11 Aug 2010

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

Novo Nordisk announced today that the U.S. Food and Drug Administration has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature (at or below 77 degrees Fahrenheit).

11 Aug 2010

Acoustic cardiography improves diagnostic accuracy in acute heart failure

It allows them to hear the S3, an abnormal third sound in the heart's rhythm strongly associated with cardiac disease and heart failure. However, the low-frequency, low-pitch sound is notoriously very difficult to hear with a stethoscope alone.It allows them to hear the S3, an abnormal third sound in the heart's rhythm strongly associated with cardiac disease and heart failure. However, the low-frequency, low-pitch sound is notoriously very difficult to hear with a stethoscope alone.

11 Aug 2010

Today's Opinions and Editorials: Bringing down health care costs; More on the Medicare trustees report

Short of transforming the medical payment system, can we bring down health care costs by feasible fixes? Yes, by reducing the number of services that must be covered by every insurance policy and requiring higher copayments for patients using the highest cost providers (Robert Pozen, 8/10).

11 Aug 2010

Telephone monitoring can save heart failure patients: Study

Chronic heart failure needs constant care and regular monitoring. Now research says remote monitoring, either over the phone or using wireless technology, helps people with heart failure live longer and stay out of hospital.

10 Aug 2010

Quick-Med develops new NIMBUS Advanced Active prototype wound dressing

Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.

10 Aug 2010

Inhibitex reports net loss of $5.6 million for second-quarter 2010

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

YM BioSciences Inc., announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.

10 Aug 2010

Beryl Institute publishes White paper on patient experience from different healthcare organizations

The Beryl Institute has published a new White Paper, Zeroing in on the Patient Experience: Views and Voices from the Frontlines, which takes a close look into the efforts of three patient experience leaders from different healthcare organizations. The White Paper covers what it takes to launch and sustain patient experience efforts and includes practical advice and tips for hospitals that want to begin to focus on improving the patient experience.

10 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Older Americans suffer from full-blown depression: Report

Maureen Duffy's memories of her grandmother are cloudy. Not because of time, but by a condition that cast a shadow over the woman Duffy had visited as a child.

10 Aug 2010

CGI receive contract for chronic disease management system

eHealth Ontario and Infrastructure Ontario announced today that with the awarding of a contract to CGI Information Systems and Management Consultants Inc., a subsidiary of CGI Group Inc., work can begin on a chronic disease management system (CDMS) that will be used initially as a Diabetes Registry to manage diabetes care.

10 Aug 2010

Mild sleep restriction for several nights can affect cognitive tasks: Research

Many people are sleep restricted, either because they have to or because they choose to be, she says. "Instead of going to bed when they are tired, like they should, people watch TV and want to have an active social life," she says. "People count on catching up on their sleep on the weekends, but it may not be enough."

10 Aug 2010

Study on ethnic disparities in pediatric asthma in Latino and non-Latino children

A new study by researchers at the Bradley Hasbro Children's Research Center and the University of Puerto Rico may help explain some of the well-documented ethnic disparities in pediatric asthma.

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

Study suggests reimbursements can address inappropriate antibiotic usage

Antibiotic use appears to have increased among older adults whose prescription drug coverage improved as a result of enrolling in Medicare Part D, with the largest increases for broad-spectrum, newer and more expensive drugs, according to a report in the August 9/23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

10 Aug 2010

Scientists work towards creating a vaccine for Parkinson's disease

Nina Brown, 68, and millions of others with a debilitating neurological condition called Parkinson's disease are counting on researchers for a cure. At The University of Texas Health Science Center at Houston (UTHealth), protein chemists are working to develop a therapeutic vaccine.

10 Aug 2010